Relationship between <scp>tRNA</scp>‐derived fragments and human cancers

Zeng, Tianyu; Hua, Yijia; Sun, Chunxiao; Zhang, Yuchen; Yang, Fan; Yang, Mingli; Yang, Yiqi; Li, Jun; Huang, Xiang; Wu, Hao; Fu, Ziyi; Li, Wei; Yin, Yuan

doi:10.1002/ijc.33107

Cited by 41 publications

(40 citation statements)

References 95 publications

(212 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Both subtypes of tsRNA are closely related to the development of tumors [14,20,21]. For example, specific tRFs derived from tRNA-Glu, tRNA-Asp, tRNA-Gly, and tRNA-Tyr suppress breast cancer by binding to Y box binding protein 1 (YBX1) and destabilizing oncogenic transcripts [22].…”

Section: Introductionmentioning

confidence: 99%

A specific tRNA half, 5’tiRNA-His-GTG, responds to hypoxia via the HIF1α/ANG axis and promotes colorectal cancer progression by regulating LATS2

Tao

Wang

Cheng

et al. 2021

J Exp Clin Cancer Res

View full text Add to dashboard Cite

Background Currently, tRNA-derived small RNAs (tsRNAs) are recognized as a novel and potential type of non-coding RNAs (ncRNAs), which participate in various cellular processes and play an essential role in cancer progression. However, tsRNAs involvement in colorectal cancer (CRC) progression remains unclear. Methods Sequencing analyses were performed to explore the tsRNAs with differential expression in CRC. Gain- and loss-of functions of 5’tiRNA-His-GTG were performed in CRC cells and xenograft tumor to discover its role in the progression of CRC. Hypoxia culture and hypoxia inducible factor 1 subunit alpha (HIF1α) inhibitors were performed to uncover the biogenesis of 5’tiRNA-His-GTG. The regulation of 5’tiRNA-His-GTG for large tumor suppressor kinase 2 (LATS2) were identified by luciferase reporter assay, western blot, and rescue experiments. Results Here, our study uncovered the profile of tsRNAs in human CRC tissues and confirmed a specific tRNA half, 5’tiRNA-His-GTG, is upregulated in CRC tissues. Then, in vitro and in vivo experiments revealed the oncogenic role of 5’tiRNA-His-GTG in CRC and found that targeting 5’tiRNA-His-GTG can induce cell apoptosis. Mechanistically, the generation of 5’tiRNA-His-GTG seems to be a responsive process of tumor hypoxic microenvironment, and it is regulated via the HIF1α/angiogenin (ANG) axis. Remarkably, LATS2 was found to be an important and major target of 5’tiRNA-His-GTG, which renders 5’tiRNA-His-GTG to “turn off” hippo signaling pathway and finally promotes the expression of pro-proliferation and anti-apoptosis related genes. Conclusions In summary, the findings revealed a specific 5’tiRNA-His-GTG-engaged pathway in CRC progression and provided clues to design a novel therapeutic target in CRC.

show abstract

Section: Introductionmentioning

confidence: 99%

A specific tRNA half, 5’tiRNA-His-GTG, responds to hypoxia via the HIF1α/ANG axis and promotes colorectal cancer progression by regulating LATS2

Tao

Wang

Cheng

et al. 2021

J Exp Clin Cancer Res

View full text Add to dashboard Cite

show abstract

“…5′-tRF-Lys TTT , 5′-tRF-Val CAC , 5′-tRF-Glu CTC , 5′-tRF-Pro CGG tRF-5 Associate with chemotherapy treatment outcomes [26] prostate cancer tRF-1001 tRF-1 TRF-1001 is required for cell proliferation. [31] tRNA Lys-CTT tRNA Phe-GAA tRF The ratio of tRFs derived from tRNA Lys-CTT and tRNA Phe-GAA is a good indicator of progression-free survival.…”

Section: Mechanisms Of Breast Cancer Resistance Related To Trfs and Tmentioning

confidence: 99%

“…These two mutations are involved in the resistance of breast cancer cells to lapatinib. [26] lung cancer tRF-Leu-CAG tRF-Leu-CAG may be related to AURKA. AURKA overexpression induces gefitinib and cisplatin resistance.…”

Section: Mechanisms Of Breast Cancer Resistance Related To Trfs and Tmentioning

confidence: 99%

See 1 more Smart Citation

Mechanisms of tRNA-derived fragments and tRNA halves in cancer treatment resistance

Zhang

Qian

et al. 2020

Biomark Res

View full text Add to dashboard Cite

The tRNA-derived fragments (tRFs) and tRNA halves (tiRNAs) are newly discovered noncoding RNAs in recent years. They are derived from specific cleavage of mature and pre-tRNAs and expressed in various cancers. They enhance cell proliferation and metastasis or inhibit cancer progression. Many studies have investigated their roles in the diagnosis, progression, metastasis, and prognosis of various cancers, but the mechanisms through which they are involved in resistance to cancer treatment are unclear. This review outlines the classification of tRFs and tiRNAs and their mechanisms in cancer drug resistance, thus providing new ideas for cancer treatment.

show abstract

“…Previous research has shown that the underlying mechanism of tRF regulates various human diseases such as cancers, pathological stress injuries, metabolic diseases, viral infections, and nervous system diseases [14][15][16]. However, the understanding of how tRF regulates cancer progression is still in its infancy [17].…”

Section: Introductionmentioning

confidence: 99%

A Comprehensive Expression Profile of tRNA-Derived Fragments in Papillary Thyroid Cancer

Shan

Wang

Zhu

2020

JSO

View full text Add to dashboard Cite

Objective: In recent years, the incidence of thyroid cancer has been increasing. Papillary thyroid cancer (PTC) is the most common type of malignant thyroid tumor, accounting for approximately 85% of thyroid cancer cases. Although the genetic background of PTC has been studied extensively, relatively little is known about the role of small non-coding RNA (sncRNA) in this disease. tRNA-derived fragments (tRFs) represent a newly discovered class of sncRNAs that exist in many species and play a role in many biological processes. Methods: In this study, we used RNA sequencing to analyse the expression of tRFs in fresh frozen specimens from PTC tissues and normal tissues adjacent to the tumors. Through this analysis, we identified 49 unique tRFs and transfer RNA halves and then performed quantitative PCR to determine the expression levels of these molecules and to make bioinformatic predictions. Conclusion: In this report, we provide a comprehensive catalog of tRFs in PTC and assess the abnormal expression of these fragments. These preliminary findings can be used as the basis for further research regarding the functional role of tRFs in patients with PTC.

show abstract

Relationship between tRNA‐derived fragments and human cancers

Cited by 41 publications

References 95 publications

A specific tRNA half, 5’tiRNA-His-GTG, responds to hypoxia via the HIF1α/ANG axis and promotes colorectal cancer progression by regulating LATS2

A specific tRNA half, 5’tiRNA-His-GTG, responds to hypoxia via the HIF1α/ANG axis and promotes colorectal cancer progression by regulating LATS2

Mechanisms of tRNA-derived fragments and tRNA halves in cancer treatment resistance

A Comprehensive Expression Profile of tRNA-Derived Fragments in Papillary Thyroid Cancer

Contact Info

Product

Resources

About